ASX/Media Release



6/02/2020

Schedule of Commitments

Perth, Australia; 6 February 2020: Emerald Clinics Limited (ASX:EMD or the Company) advises that the Company raised \$6,000,000 under the Public Offer pursuant to the prospectus dated 11 December 2019 (**Prospectus**).

As set out in the Prospectus the following table shows the intended use of funds together with the existing cash reserves in the one-year period following Admission:

Source of funds	(\$)
Existing cash as at the date of the Prospectus	1,700,000
Proceeds from the Public Offer	6,000,000
Total funds available	7,700,000
Use of Funds	(\$)
Clinic Operations - Existing	2,500,000
Develop Data Platform	800,000
Clinical Trials	800,000
Clinic Development – New and Existing	800,000
Corporate Overheads	1,600,000
Costs of the Offers	682,300
Working capital	517,700
Total Expenditure	7,700,000

Notes:

- The above estimated expenditures will be subject to modification on an ongoing basis depending on the results obtained from the Company's activities. Due to market conditions, the development of new opportunities and/or any number of other factors (including the risk factors outlined in Section 4 of the Prospectus), actual expenditure levels may differ significantly from the above estimates.
- 2. For further details refer to Section 1.8 or the Prospectus.

Simon Robertson Company Secretary



About Emerald Clinics Limited

Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company that operates a network of specialist medical clinics (Clinics) and uses purpose-built software and technology to gather high quality clinical data from informed and consenting patients.

Emerald is a clinical services and healthcare technology company focussed on the provision of care for patients clinically determined to have exhausted conventional therapies and who may be suitable for cannabinoid-based medicines. In addition, Emerald uses technology to capture clinical data that can be used to generate clinical evidence relating to the safety and efficacy of unregistered medicines.

Emerald has established four medical centres in Australia including one site each in West Leederville WA, Woolloomooloo NSW, Tintenbar NSW and Richmond VIC.

For more information, please contact:

General enquiries	Investor and Media enquiries
Emerald Clinics Limited	Matthew Wright
P: +61 8 6559 2800	NWR Communications
admin@emeraldclinics.com.au	matt@nwrcommunications.com.au

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.